Biochemistry, Genetics and Molecular Biology
Activating Transcription Factor
50%
Adaptive Immunity
50%
Biomarker Research
100%
Cancer Cell
50%
Chemokine
50%
Chemokine Receptor
50%
Clinical Decision Making
50%
Clinical Research
50%
Cooperation
50%
Gene Expression Profiling
50%
Immune Checkpoints
50%
Mycobacterium Bovis BCG
50%
Peroxisome Proliferator-Activated Receptor Gamma
50%
Regulon
50%
Subtyping
100%
Transcriptomics
50%
Keyphrases
13th
5%
Aarhus
5%
Abstract Submission
5%
Adaptive Immunity
5%
Alpha Expressions
5%
ATLAS Project
5%
Atypical Chemokine Receptor 3
5%
Bacillus Calmette-Guérin Therapy
5%
Basal-like
5%
Biomarker Research
10%
Bladder Cancer
100%
Bladder Cancer Cells
5%
Bladder Tumor
5%
Bladder-sparing
5%
Breakout
5%
Canada
5%
Cancer Genome Atlas
5%
Cancer Genomics
5%
Cancer Networks
63%
Cancer Patients
5%
Cancer Research
100%
Cell Line Models
5%
Chemokines
5%
Clinical Biomarkers
10%
Clinical Decision-making
5%
Clinical Research
5%
Clinical Topics
10%
Close Cooperation
5%
Combined Modality Therapy
10%
Consensus Classification
5%
Consensus Conference
5%
Denmark
5%
Educational Training
5%
France
10%
Gender Disparity
5%
Gene Expression Analysis
5%
Genetic Identification
5%
Genomic Classification
5%
Genomic Heterogeneity
5%
Genomic Subtyping
10%
Germany
5%
Global Demand
5%
Health Systems
5%
Histology
10%
Immune Checkpoint Inhibitors
5%
Immunotherapy Trials
5%
Improved Survival
5%
In Cancer
5%
Industry Representatives
5%
Keynote Lectures
5%
Metabolic Processes
5%
Metastasis
5%
Metastasizing
5%
Molecular Classification
21%
Molecular Subtypes
5%
Muscle-invasive Bladder Cancer
42%
Netherlands
10%
Network Meeting
10%
New Formats
5%
Nidus
5%
Novel Therapeutic Targets
10%
Number of Participants
5%
Organizational Challenges
5%
Oxford
5%
Peroxisome Proliferator-activated Receptor
5%
Poster Sessions
5%
Posters
5%
Primary Tumor
10%
Radical Cystectomy
5%
Rapid Evolution
5%
Registry-based
5%
Regulon
5%
Rotterdam
10%
Small Cell Bladder Cancer
5%
Spatial Heterogeneity
5%
Spatiotemporal Heterogeneity
5%
Subclassification
5%
Survival Outcomes
5%
Switzerland
5%
Systemic Immune Response
5%
Take-home
5%
Traditional Industries
5%
Training Background
5%
Transcription Factor
5%
Transcriptional Circuits
5%
Transcriptional Heterogeneity
5%
Transcriptional Repression
5%
Tumor Heterogeneity
5%
Urologic Oncology
5%
Urologists
5%
Immunology and Microbiology
Activating Transcription Factor
50%
Adaptive Immune System
50%
Cancer Cell
50%
Cell Line
50%
Chemokine
50%
Chemokine Receptor
50%
Clinical Decision Making
50%
Gene Expression Profiling
50%
Immunotherapy
100%
Mycobacterium Bovis BCG
50%
Peroxisome
50%
Regulon
50%
Transcriptomics
50%
Neuroscience
Activating Transcription Factor
50%
Adaptive Immunity
50%
Cell Line
50%
Chemokine
50%
Chemokine Receptor
50%
Clinical Decision Making
50%
Expression Analysis
50%
Gene Expression
50%
Immunotherapy
100%
Peroxisome Proliferator-Activated Receptor Gamma
50%
Regulon
50%
Transcriptomics
50%
Urological
50%
Medicine and Dentistry
Activating Transcription Factor
4%
Adaptive Immunity
4%
Biological Marker
9%
Bladder
4%
Bladder Cancer
100%
Bladder Tumor
4%
Cancer Cell
4%
Cancer Research
100%
Cell Line
4%
Chemokine
4%
Chemokine Receptor
4%
Clinical Decision Making
4%
Clinical Research
4%
Cooperation
4%
Cystectomy
4%
Epidemic
4%
Gene Expression Profiling
4%
Health Care Cost
9%
Health System
4%
Immune Checkpoint Inhibitor
4%
Immunotherapy
9%
Malignant Neoplasm
9%
Metastatic Carcinoma
4%
Muscle Invasive Bladder Cancer
38%
Mycobacterium Bovis BCG
4%
Peroxisome Proliferator Activated Receptor Gamma
4%
Primary Tumor
9%
Regulon
4%
Transcriptomics
4%
Tumour Heterogeneity
4%
Urologic Oncology
4%
Urologist
4%
Pharmacology, Toxicology and Pharmaceutical Science
Activating Transcription Factor
4%
Biological Marker
9%
Bladder Cancer
100%
Bladder Tumor
4%
Chemokine
4%
Chemokine Receptor
4%
Clinical Research
4%
Immune Checkpoint Inhibitor
4%
Immunotherapy
9%
Malignant Neoplasm
9%
Muscle Invasive Bladder Cancer
38%
Mycobacterium Bovis BCG
4%
Neoplasm
4%
Peroxisome Proliferator Activated Receptor Gamma
4%
Primary Tumor
9%